// App-Quantinova.ai

: Low-Dose Nivolumab Plus Brentuximab Vedotin As a Bridge to Stem Cell Transplantation in Relapsed/Refractory Classical Hodgkin Lymphoma

Researchers

Presenter

  • Perla R. R. Colunga-Pedraza

Principal Investigators

  • Edgar Ulises Coronado-Alejandro

  • Fernando De La Garza

  • Eliezer Tomas Gomez Gomez

  • Andres Gomez-de Leon

  • Julia Esther Colunga Pedraza

  • Cesar Homero Gutierrez-Aguirre

  • Olga Graciela Cantu Rodriguez

  • David Gomez-Almaguer

Medical Centers

  • N/A

Locations

  • Mexico

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Hodgkin's Lymphoma

Biomarkers

  • N/A

Drug/Treatment

  • brentuximab vedotin

  • Adcetris

  • Nivolumab

Outcome

  • N/A

Study Design

  • Fixed Dose

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved